Anti-MAG First Administration to Human

Completed

Phase 1 Results N/A

Summary of Purpose

GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 July 2017.

1 Aug 2007 13 Feb 2008 9 Apr 2009 9 Apr 2009 1 Jul 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Subject)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts

Not available